Raabia N Ahmad, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 30
- 10 carriers
- Office
- 1
- Since medical school
- 16 years
- Drexel University College of Medicine, 2010
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
30 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ahmad’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Aetna Medicare Eagle (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Aetna Medicare Enhanced (PPO) | Aetna Medicare | Listed | Sep 8, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$483,261
Medicare paid this office $483,261 for 1,202 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 515 | $121,511 | $112 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 134 | $62,166 | $464 |
| Ultrasound of both sides of head and neck blood flow | 169 | $32,922 | $191 |
| Long return visit (40+ min) | 149 | $29,814 | $159 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 163 | $29,729 | $178 |
See all 35 services
| Return visit (30+ min) | 515 | $121,511 | $112 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 134 | $62,166 | $464 |
| Ultrasound of both sides of head and neck blood flow | 169 | $32,922 | $191 |
| Long return visit (40+ min) | 149 | $29,814 | $159 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 163 | $29,729 | $178 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 91 | $26,049 | $271 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 75 | $23,569 | $106 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 137 | $20,560 | $75 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $11,541 | $144 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 178 | $10,435 | $58 |
| Ultrasound of leg arteries or artery grafts | 37 | $9,249 | $250 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 30 | $9,147 | $295 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 144 | $9,100 | $63 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 33 | $8,936 | $271 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 160 | $7,650 | $24 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 35 | $6,363 | $182 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 409 | $6,004 | $13 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 37 | $5,416 | $146 |
| Programming of dual lead pacemaker system | 59 | $4,942 | $50 |
| Critical care, first 30-74 minutes | 14 | $4,651 | $186 |
| New patient visit (45+ min) | 27 | $4,158 | $154 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 59 | $3,960 | $31 |
| New patient visit (60+ min) | 19 | $3,773 | $199 |
| Short return visit (20+ min) | 35 | $3,135 | $80 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $2,815 | $235 |
| Ultrasound study of arm and leg arteries | 37 | $2,447 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,874 | $67 |
| Programming of dual lead implantable defibrillator system | 13 | $1,386 | $73 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 14 | $1,360 | $22 |
| External shock to heart to regulate heart beat | 14 | $1,337 | $96 |
| Injection, regadenoson, 0.1 mg | 67 | $1,287 | None |
| Ultrasound of heart blood flow, valves and chambers | 12 | $587 | $49 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 31 | $489 | $15 |
| Blood test, clotting time | 13 | $370 | $4 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $283 | $24 |
Who their Medicare patients are
1,202 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 30% · Women 47% · Also on Medicaid 13% · Health risk score 1.49. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 52% · Atrial fibrillation 39% · Diabetes 34% · Heart failure 34% · Chronic kidney disease 28% · Cancer 19% · Depression 16% · COPD 14% · Dementia 12% · Stroke 12%.
The office billed $2,142,913, Medicare allowed $643,605 and paid $483,261; for 4,776 services of 66 kinds; $1,288 of it was for drugs given in the office and $481,973 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,202 | 4,776 | 79 | 1.49 | $2,142,913 | $483,261 |
| 2023 | 1,085 | 3,950 | 79 | 1.37 | $1,707,605 | $405,998 |
| 2022 | 986 | 4,138 | 79 | 1.23 | $1,832,349 | $434,479 |
| 2021 | 695 | 2,535 | 79 | 1.16 | $1,082,568 | $278,244 |
| 2020 | 1,407 | 2,876 | 76 | 1.91 | $640,911 | $108,989 |
| 2019 | 1,834 | 3,987 | 75 | 1.88 | $816,164 | $155,248 |
| 2018 | 2,545 | 5,789 | 75 | 1.83 | $1,260,133 | $246,397 |
| 2017 | 2,474 | 5,388 | 75 | 1.84 | $1,080,380 | $225,571 |
| 2016 | 1,041 | 1,834 | 75 | 1.90 | $319,857 | $70,391 |
| 2015 | 15 | 19 | 73 | 2.89 | $3,814 | $1,778 |
| 2014 | 11 | 15 | 80 | 2.34 | $3,040 | $1,444 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 37 services
| Return visit (30+ min) | 412 | $94,506 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 251 | $50,086 | $196 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 92 | $44,077 | $474 |
| Long return visit (40+ min) | 120 | $24,688 | $161 |
| Ultrasound of both sides of head and neck blood flow | 126 | $23,864 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 83 | $14,697 | $71 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 95 | $14,059 | $73 |
| Ultrasound of leg arteries or artery grafts | 44 | $11,585 | $252 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 52 | $10,418 | $200 |
| Injection, regadenoson, 0.1 mg | 51 | $9,340 | None |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 31 | $8,535 | $275 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 25 | $8,069 | $288 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 126 | $7,602 | $59 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 101 | $7,017 | $69 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 62 | $6,810 | $110 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 43 | $6,742 | $153 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 253 | $6,633 | $22 |
| Short return visit (20+ min) | 71 | $5,350 | $69 |
| New patient visit (45+ min) | 37 | $4,762 | $129 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 315 | $4,519 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,516 | $105 |
| New patient visit (60+ min) | 18 | $3,722 | $207 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 12 | $3,640 | $303 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,596 | $144 |
| Ultrasound study of arm and leg arteries | 44 | $3,170 | $69 |
| Programming of dual lead pacemaker system | 41 | $2,301 | $33 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $2,256 | $84 |
| External shock to heart to regulate heart beat | 15 | $1,771 | $98 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,598 | $94 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 52 | $1,401 | $27 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $690 | $53 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 20 | $665 | $33 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 26 | $574 | $21 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $574 | $44 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 26 | $358 | $13 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 12 | $282 | $23 |
| Blood test, clotting time | 16 | $206 | $4 |
2022: 32 services
| Return visit (30+ min) | 355 | $88,415 | $115 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 161 | $79,642 | $480 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 236 | $48,607 | $203 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 167 | $27,954 | $83 |
| Ultrasound of both sides of head and neck blood flow | 119 | $24,126 | $201 |
| Long return visit (40+ min) | 106 | $22,895 | $160 |
| Injection, regadenoson, 0.1 mg | 96 | $18,871 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 168 | $12,210 | $71 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 45 | $9,265 | $197 |
| Ultrasound of leg arteries or artery grafts | 33 | $8,732 | $257 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 30 | $8,452 | $282 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $7,463 | $63 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 243 | $6,851 | $22 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 97 | $6,261 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $5,523 | $92 |
| New patient visit (45+ min) | 37 | $5,149 | $139 |
| Short return visit (20+ min) | 62 | $5,094 | $73 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 28 | $4,556 | $157 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 283 | $4,410 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $4,248 | $121 |
| New patient visit (60+ min) | 19 | $3,768 | $198 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,720 | $177 |
| Telephone medical discussion with physician, 11-20 minutes | 36 | $2,682 | $65 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,414 | $97 |
| Ultrasound study of arm and leg arteries | 33 | $2,389 | $70 |
| Programming of dual lead pacemaker system | 33 | $1,976 | $33 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,079 | $98 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 39 | $954 | $22 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 39 | $658 | $15 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 25 | $644 | $24 |
| Blood test, clotting time | 40 | $429 | $4 |
| Heart rhythm recording of continous external ekg over 8-15 days | 25 | $388 | $15 |
2021: 28 services
| Return visit (30+ min) | 222 | $46,583 | $124 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 169 | $35,877 | $207 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $34,466 | $500 |
| Long return visit (40+ min) | 131 | $27,906 | $173 |
| Ultrasound of both sides of head and neck blood flow | 82 | $17,629 | $198 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 73 | $13,154 | $89 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 30 | $9,345 | $267 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 38 | $8,304 | $203 |
| Injection, regadenoson, 0.1 mg | 43 | $8,190 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $6,438 | $66 |
| Ultrasound of leg arteries or artery grafts | 22 | $6,290 | $252 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 80 | $5,764 | $72 |
| Short return visit (20+ min) | 56 | $5,708 | $89 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 214 | $5,424 | $23 |
| New patient visit (45+ min) | 32 | $5,116 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,534 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 57 | $3,658 | $64 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 20 | $3,476 | $151 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,471 | $124 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 222 | $3,407 | $14 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,747 | $183 |
| Ultrasound study of arm and leg arteries | 22 | $1,671 | $67 |
| Programming of dual lead pacemaker system | 27 | $1,032 | $36 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 22 | $549 | $23 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 23 | $410 | $16 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 14 | $352 | $25 |
| Blood test, clotting time | 35 | $262 | $4 |
| Heart rhythm recording of continous external ekg over 8-15 days | 14 | $234 | $17 |
2020: 29 services
| Return visit (30+ min) | 348 | $28,030 | $69 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 114 | $9,151 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 78 | $8,123 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 142 | $7,773 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $6,675 | $117 |
| Telephone medical discussion with physician, 11-20 minutes | 90 | $5,122 | $54 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 328 | $4,644 | $12 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,870 | $155 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $3,468 | $94 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 401 | $3,405 | $7 |
| Telephone medical discussion with physician, 21-30 minutes | 39 | $3,193 | $82 |
| Long return visit (40+ min) | 32 | $3,171 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 44 | $2,568 | $58 |
| New patient visit (45+ min) | 17 | $1,803 | $106 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,501 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,415 | $88 |
| Telephone medical discussion with physician, 5-10 minutes | 32 | $1,105 | $31 |
| Short return visit (20+ min) | 20 | $963 | $44 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 59 | $946 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 29 | $936 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 49 | $730 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 59 | $637 | $11 |
| Blood test, clotting time | 19 | $561 | $4 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 82 | $552 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 49 | $519 | $10 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 22 | $404 | $18 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 37 | $269 | $6 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 17 | $114 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $57 | $3 |
2019: 31 services
| Return visit (30+ min) | 485 | $56,547 | $81 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 140 | $13,220 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 172 | $9,636 | $56 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 512 | $9,309 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 78 | $8,199 | $59 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 774 | $6,894 | $7 |
| New patient visit (45+ min) | 51 | $6,559 | $129 |
| Long return visit (40+ min) | 43 | $6,408 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 51 | $5,865 | $115 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 52 | $5,381 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,467 | $165 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 36 | $2,265 | $63 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,571 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,222 | $87 |
| External shock to heart to regulate heart beat | 13 | $1,214 | $93 |
| Short return visit (20+ min) | 18 | $1,051 | $53 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 59 | $1,039 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 66 | $1,026 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 34 | $910 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 59 | $699 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 66 | $686 | $10 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 30 | $625 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 11 | $609 | $55 |
| Short return visit | 13 | $547 | $34 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 58 | $540 | $6 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 61 | $492 | $7 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 17 | $364 | $21 |
| Blood test, clotting time | 22 | $347 | $4 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 18 | $312 | $17 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 15 | $94 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 26 | $69 | $3 |
2018: 35 services
| Return visit (30+ min) | 609 | $80,601 | $81 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 225 | $21,957 | $98 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 118 | $19,987 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 161 | $19,147 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 224 | $12,838 | $57 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 644 | $12,356 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 105 | $12,252 | $112 |
| New patient visit (45+ min) | 76 | $9,713 | $128 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,089 | $9,002 | $7 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 36 | $6,673 | $93 |
| Short return visit (20+ min) | 92 | $5,840 | $57 |
| Injection, regadenoson, 0.1 mg | 25 | $4,434 | None |
| Long return visit (40+ min) | 28 | $3,499 | $121 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 54 | $3,490 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 39 | $2,130 | $53 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 114 | $1,914 | $17 |
| Ultrasound of heart with probe in esophagus, with report | 19 | $1,812 | $91 |
| New patient visit (45+ min) | 16 | $1,663 | $104 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,417 | $79 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 83 | $1,402 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 114 | $1,277 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 83 | $948 | $11 |
| External shock to heart to regulate heart beat | 11 | $932 | $85 |
| Return visit (30+ min) | 13 | $843 | $65 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 42 | $834 | $17 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 92 | $739 | $6 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 33 | $723 | $22 |
| Follow-up observation care per day, typically 25 minutes | 11 | $665 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 93 | $616 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 26 | $599 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 18 | $378 | $21 |
| External ekg recording for more than 48 hours up to 21 days | 12 | $299 | $25 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $227 | $15 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 12 | $70 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 25 | $67 | $3 |
2017: 34 services
| Return visit (30+ min) | 563 | $71,959 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 256 | $22,232 | $86 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 93 | $17,294 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 111 | $16,402 | $59 |
| New patient visit (45+ min) | 106 | $13,208 | $125 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 107 | $12,513 | $111 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 576 | $10,848 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,092 | $9,433 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 172 | $8,788 | $51 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 33 | $6,086 | $92 |
| Injection, regadenoson, 0.1 mg | 21 | $3,647 | None |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 55 | $3,547 | $64 |
| Short return visit (20+ min) | 53 | $3,038 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 42 | $2,459 | $57 |
| Long return visit (40+ min) | 15 | $2,255 | $119 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 105 | $1,818 | $17 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,814 | $165 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,435 | $90 |
| Long return visit (40+ min) | 15 | $1,357 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 71 | $1,298 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 105 | $1,213 | $11 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 51 | $1,109 | $16 |
| Injection of drug or substance into vein | 20 | $963 | $48 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 14 | $913 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 71 | $873 | $12 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 90 | $809 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 38 | $747 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 81 | $664 | $7 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 18 | $386 | $20 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 16 | $327 | $20 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 12 | $235 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 11 | $214 | $19 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $210 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 21 | $55 | $3 |
2016: 18 services
| Return visit (30+ min) | 210 | $22,356 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 64 | $7,103 | $109 |
| New patient visit (45+ min) | 44 | $5,723 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $5,134 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 613 | $5,085 | $7 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 16 | $3,777 | $236 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 25 | $3,499 | $140 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 208 | $3,368 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 51 | $2,675 | $51 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 16 | $1,023 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 15 | $876 | $58 |
| Return visit (30+ min) | 14 | $836 | $60 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 22 | $393 | $18 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $361 | $15 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 17 | $305 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 22 | $258 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 17 | $199 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 22 | $150 | $7 |
Medicaid work
$844 in 2024
Medicaid paid $844 for 166 billed services this clinician did in 2024, up to 93 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 151 | $761 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 15 | $83 |
| 2024 | 166 | 2 | 93 | $844 |
| 2023 | 193 | 2 | 82 | $1,367 |
| 2022 | 155 | 2 | 65 | $872 |
| 2020 | 648 | 4 | 100 | $5,826 |
| 2019 | 1,258 | 4 | 161 | $11,906 |
| 2018 | 1,834 | 6 | 167 | $21,446 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 167 | $913 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 26 | $455 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 143 | $620 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 12 | $251 |
2020
| Return visit (30+ min) | 52 | $2,044 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 473 | $1,814 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 58 | $1,583 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 65 | $384 |
2019
| Return visit (30+ min) | 128 | $4,322 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 110 | $3,937 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 850 | $2,694 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 170 | $953 |
2018
| Return visit (30+ min) | 204 | $8,792 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 159 | $6,162 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,218 | $4,752 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 220 | $1,442 |
| CARDIOVASCULAR STRESS TEST | 17 | $182 |
| CARDIOVASCULAR STRESS TEST | 16 | $115 |
Drugs they prescribed that Part D paid
$1,641,522
Pharmacies billed $1,641,522 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 6,113) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
4,919 generic and 1,194 brand-name prescriptions · $1,641,522 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 298 | $423,307 | $1,420 |
| Eliquis | 273 | $391,463 | $1,434 |
| Entresto | 131 | $175,497 | $1,340 |
| Repatha Sureclick | 131 | $152,148 | $1,161 |
| Ozempic | 92 | $114,152 | $1,241 |
See all 53 drugs
| Jardiance | 298 | $423,307 | $1,420 |
| Eliquis | 273 | $391,463 | $1,434 |
| Entresto | 131 | $175,497 | $1,340 |
| Repatha Sureclick | 131 | $152,148 | $1,161 |
| Ozempic | 92 | $114,152 | $1,241 |
| Mounjaro | 86 | $107,145 | $1,246 |
| Farxiga | 48 | $75,199 | $1,567 |
| Xarelto | 41 | $61,564 | $1,502 |
| Praluent | 25 | $19,318 | $773 |
| Rosuvastatin | 875 | $15,684 | $18 |
| Metoprolol | 576 | $9,645 | $17 |
| Valsartan | 162 | $6,057 | $37 |
| Nebivolol | 71 | $5,973 | $84 |
| Torsemide | 242 | $5,533 | $23 |
| Ezetimibe | 197 | $5,355 | $27 |
| Atorvastatin | 327 | $3,417 | $10 |
| Amlodipine Besylate | 380 | $3,286 | $9 |
| Losartan | 304 | $3,234 | $11 |
| Carvedilol | 177 | $2,116 | $12 |
| Flecainide Acetate | 44 | $1,929 | $44 |
| Diltiazem 24hr Er (Cd) | 28 | $1,827 | $65 |
| Potassium Chloride | 75 | $1,525 | $20 |
| Lisinopril | 128 | $1,239 | $10 |
| Digoxin | 39 | $1,237 | $32 |
| Spironolactone | 111 | $1,181 | $11 |
| Clopidogrel | 72 | $1,127 | $16 |
| Amiodarone | 45 | $1,030 | $23 |
| Isosorbide Mononitrate Er | 59 | $808 | $14 |
| Hydrochlorothiazide | 146 | $800 | $5 |
| Sotalol | 19 | $718 | $38 |
| Simvastatin | 102 | $627 | $6 |
| Levothyroxine | 39 | $617 | $16 |
| Atenolol | 23 | $593 | $26 |
| Diltiazem 24hr Er (Xr) | 11 | $583 | $53 |
| Verapamil Er | 13 | $549 | $42 |
| Ramipril | 39 | $513 | $13 |
| Doxazosin Mesylate | 25 | $509 | $20 |
| Nifedipine Er | 14 | $498 | $36 |
| Metoprolol | 70 | $476 | $7 |
| Klor-Con 10 | 16 | $444 | $28 |
| Propranolol | 11 | $428 | $39 |
| Losartan-Hydrochlorothiazide | 38 | $359 | $9 |
| Warfarin | 33 | $354 | $11 |
| Benazepril | 30 | $340 | $11 |
| Pantoprazole | 15 | $331 | $22 |
| Valsartan-Hydrochlorothiazide | 19 | $281 | $15 |
| Metformin | 27 | $265 | $10 |
| Nitroglycerin | 28 | $259 | $9 |
| Furosemide | 45 | $166 | $4 |
| Bisoprolol | 12 | $152 | $13 |
| Omeprazole | 12 | $138 | $11 |
| Irbesartan | 16 | $82 | $5 |
| Triamterene-Hydrochlorothiazid | 12 | $81 | $7 |
Year by year
| 2024 | 6,113 | 698 | 0% (0) | 20% | $1,641,522 |
| 2023 | 4,453 | 495 | 0% (0) | None | $868,126 |
| 2022 | 3,380 | 362 | 0% (0) | 11% | $463,893 |
| 2021 | 952 | 317 | 0% (0) | 12% | $110,786 |
| 2020 | 1,842 | 444 | 0% (0) | 14% | $166,632 |
| 2019 | 3,671 | 648 | 0% (0) | 14% | $306,229 |
| 2018 | 4,634 | 728 | 0% (0) | 21% | $303,296 |
| 2017 | 3,824 | 584 | None | 22% | $209,940 |
| 2016 | 628 | 206 | 0% (0) | 26% | $28,431 |
| 2015 | 82 | 26 | None | 24% | $3,007 |
| 2014 | 146 | 35 | 0% (0) | 32% | $10,739 |
| 2013 | 47 | 21 | None | 23% | $1,408 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 47 drugs
| Eliquis | 175 | $238,254 | $1,361 |
| Jardiance | 114 | $162,077 | $1,422 |
| Ozempic | 57 | $87,111 | $1,528 |
| Entresto | 51 | $66,659 | $1,307 |
| Xarelto | 48 | $62,258 | $1,297 |
| Repatha Sureclick | 42 | $57,158 | $1,361 |
| Farxiga | 25 | $30,669 | $1,227 |
| Rosuvastatin | 593 | $17,197 | $29 |
| Ezetimibe | 160 | $10,879 | $68 |
| Metoprolol | 450 | $9,335 | $21 |
| Valsartan | 150 | $6,964 | $46 |
| Nebivolol | 53 | $5,861 | $111 |
| Torsemide | 161 | $4,821 | $30 |
| Atorvastatin | 294 | $4,213 | $14 |
| Amlodipine Besylate | 342 | $3,446 | $10 |
| Potassium Chloride | 92 | $3,284 | $36 |
| Carvedilol | 169 | $2,974 | $18 |
| Losartan | 193 | $2,757 | $14 |
| Lisinopril | 136 | $1,656 | $12 |
| Diltiazem 24hr Er (Xr) | 17 | $1,623 | $95 |
| Diltiazem 24hr Er (Cd) | 24 | $1,571 | $65 |
| Ezetimibe-Simvastatin | 12 | $1,449 | $121 |
| Amiodarone | 35 | $1,215 | $35 |
| Flecainide Acetate | 14 | $1,150 | $82 |
| Isosorbide Mononitrate Er | 48 | $1,148 | $24 |
| Sotalol | 21 | $967 | $46 |
| Doxazosin Mesylate | 31 | $936 | $30 |
| Hydrochlorothiazide | 135 | $903 | $7 |
| Clopidogrel | 58 | $861 | $15 |
| Valsartan-Hydrochlorothiazide | 11 | $837 | $76 |
| Bumetanide | 13 | $806 | $62 |
| Digoxin | 23 | $787 | $34 |
| Metoprolol | 61 | $642 | $11 |
| Simvastatin | 79 | $530 | $7 |
| Benazepril | 25 | $510 | $20 |
| Atenolol | 26 | $495 | $19 |
| Losartan-Hydrochlorothiazide | 24 | $466 | $19 |
| Ramipril | 45 | $446 | $10 |
| Spironolactone | 34 | $422 | $12 |
| Pantoprazole | 20 | $414 | $21 |
| Furosemide | 51 | $399 | $8 |
| Levothyroxine | 18 | $397 | $22 |
| Nitroglycerin | 21 | $256 | $12 |
| Irbesartan | 15 | $218 | $15 |
| Pravastatin | 12 | $162 | $13 |
| Metformin | 16 | $135 | $8 |
| Warfarin | 12 | $128 | $11 |
2022: 39 drugs
| Eliquis | 135 | $164,561 | $1,219 |
| Xarelto | 54 | $62,945 | $1,166 |
| Repatha Sureclick | 41 | $42,051 | $1,026 |
| Entresto | 29 | $33,854 | $1,167 |
| Ozempic | 24 | $26,976 | $1,124 |
| Rosuvastatin | 466 | $23,720 | $51 |
| Ezetimibe | 117 | $11,100 | $95 |
| Praluent | 15 | $10,598 | $707 |
| Metoprolol | 309 | $7,417 | $24 |
| Valsartan | 93 | $4,733 | $51 |
| Atorvastatin | 250 | $4,243 | $17 |
| Carvedilol | 159 | $2,537 | $16 |
| Amlodipine Besylate | 267 | $2,505 | $9 |
| Torsemide | 94 | $2,459 | $26 |
| Losartan | 155 | $2,346 | $15 |
| Potassium Chloride | 63 | $1,865 | $30 |
| Nebivolol | 12 | $1,754 | $146 |
| Digoxin | 23 | $1,125 | $49 |
| Flecainide Acetate | 12 | $1,035 | $86 |
| Lisinopril | 104 | $1,016 | $10 |
| Sotalol | 26 | $1,009 | $39 |
| Diltiazem 24hr Er (Cd) | 22 | $974 | $44 |
| Clopidogrel | 62 | $965 | $16 |
| Hydrochlorothiazide | 115 | $874 | $8 |
| Isosorbide Mononitrate Er | 37 | $860 | $23 |
| Diltiazem 24hr Er (Xr) | 15 | $830 | $55 |
| Ramipril | 49 | $786 | $16 |
| Losartan-Hydrochlorothiazide | 28 | $776 | $28 |
| Metoprolol | 71 | $759 | $11 |
| Simvastatin | 80 | $692 | $9 |
| Amiodarone | 21 | $579 | $28 |
| Irbesartan | 14 | $427 | $30 |
| Benazepril | 18 | $419 | $23 |
| Doxazosin Mesylate | 18 | $401 | $22 |
| Nitroglycerin | 20 | $359 | $18 |
| Atenolol | 20 | $246 | $12 |
| Furosemide | 44 | $204 | $5 |
| Pravastatin | 11 | $152 | $14 |
| Warfarin | 15 | $147 | $10 |
2021: 20 drugs
| Eliquis | 46 | $42,709 | $928 |
| Repatha Sureclick | 13 | $13,685 | $1,053 |
| Rosuvastatin | 119 | $4,077 | $34 |
| Ezetimibe | 36 | $3,508 | $97 |
| Metoprolol | 89 | $2,112 | $24 |
| Atorvastatin | 70 | $1,213 | $17 |
| Valsartan | 22 | $1,137 | $52 |
| Losartan | 46 | $671 | $15 |
| Amlodipine Besylate | 86 | $581 | $7 |
| Carvedilol | 37 | $426 | $12 |
| Lisinopril | 50 | $376 | $8 |
| Torsemide | 13 | $351 | $27 |
| Losartan-Hydrochlorothiazide | 11 | $348 | $32 |
| Isosorbide Mononitrate Er | 14 | $280 | $20 |
| Clopidogrel | 22 | $266 | $12 |
| Amiodarone | 11 | $224 | $20 |
| Metoprolol | 22 | $204 | $9 |
| Furosemide | 22 | $180 | $8 |
| Simvastatin | 20 | $160 | $8 |
| Hydrochlorothiazide | 15 | $96 | $6 |
2020: 30 drugs
| Eliquis | 113 | $84,419 | $747 |
| Xarelto | 17 | $17,029 | $1,002 |
| Metoprolol | 310 | $9,595 | $31 |
| Rosuvastatin | 82 | $5,728 | $70 |
| Atorvastatin | 191 | $3,144 | $16 |
| Ezetimibe | 37 | $2,920 | $79 |
| Diltiazem 24hr Er (Cd) | 38 | $1,858 | $49 |
| Losartan | 106 | $1,723 | $16 |
| Isosorbide Mononitrate Er | 54 | $1,189 | $22 |
| Amiodarone | 13 | $1,152 | $89 |
| Warfarin | 53 | $1,068 | $20 |
| Torsemide | 35 | $1,063 | $30 |
| Digoxin | 16 | $804 | $50 |
| Valsartan | 14 | $755 | $54 |
| Lisinopril | 123 | $734 | $6 |
| Amlodipine Besylate | 107 | $732 | $7 |
| Nitroglycerin | 19 | $678 | $36 |
| Furosemide | 84 | $632 | $8 |
| Doxazosin Mesylate | 19 | $376 | $20 |
| Fenofibrate | 11 | $350 | $32 |
| Simvastatin | 43 | $315 | $7 |
| Sotalol | 11 | $292 | $27 |
| Atenolol | 32 | $283 | $9 |
| Carvedilol | 30 | $268 | $9 |
| Pantoprazole | 21 | $262 | $12 |
| Clopidogrel | 27 | $224 | $8 |
| Pravastatin | 13 | $209 | $16 |
| Hydrochlorothiazide | 40 | $188 | $5 |
| Spironolactone | 18 | $170 | $9 |
| Metoprolol | 18 | $141 | $8 |
2019: 36 drugs
| Eliquis | 214 | $135,335 | $632 |
| Xarelto | 36 | $30,617 | $850 |
| Metoprolol | 665 | $22,052 | $33 |
| Rosuvastatin | 139 | $9,694 | $70 |
| Atorvastatin | 379 | $7,352 | $19 |
| Diltiazem 24hr Er (Cd) | 88 | $6,318 | $72 |
| Ethacrynic Acid | 11 | $5,793 | $527 |
| Warfarin | 181 | $3,338 | $18 |
| Isosorbide Mononitrate Er | 59 | $2,325 | $39 |
| Losartan | 146 | $1,868 | $13 |
| Digoxin | 43 | $1,765 | $41 |
| Ezetimibe | 13 | $1,758 | $135 |
| Nitroglycerin | 26 | $1,732 | $67 |
| Lisinopril | 277 | $1,589 | $6 |
| Amlodipine Besylate | 210 | $1,475 | $7 |
| Torsemide | 65 | $1,415 | $22 |
| Doxazosin Mesylate | 41 | $1,415 | $35 |
| Furosemide | 199 | $1,293 | $6 |
| Pravastatin | 45 | $923 | $21 |
| Nitroglycerin Patch | 19 | $834 | $44 |
| Sotalol | 18 | $795 | $44 |
| Clopidogrel | 74 | $764 | $10 |
| Valsartan | 16 | $742 | $46 |
| Diltiazem 24hr Er | 13 | $723 | $56 |
| Spironolactone | 48 | $626 | $13 |
| Simvastatin | 82 | $626 | $8 |
| Amiodarone | 42 | $623 | $15 |
| Atenolol | 44 | $425 | $10 |
| Hydrochlorothiazide | 57 | $397 | $7 |
| Carvedilol | 50 | $370 | $7 |
| Pantoprazole | 14 | $351 | $25 |
| Metoprolol | 43 | $327 | $8 |
| Hydralazine | 11 | $178 | $16 |
| Lisinopril-Hydrochlorothiazide | 18 | $164 | $9 |
| Omeprazole | 17 | $105 | $6 |
| Calcitriol | 12 | $81 | $7 |
2018: 48 drugs
| Eliquis | 214 | $128,775 | $602 |
| Metoprolol | 844 | $26,216 | $31 |
| Xarelto | 26 | $16,827 | $647 |
| Entresto | 13 | $9,457 | $727 |
| Edecrin | 11 | $8,190 | $745 |
| Atorvastatin | 431 | $8,019 | $19 |
| Rosuvastatin | 130 | $7,303 | $56 |
| Diltiazem 24hr Er (Cd) | 114 | $5,216 | $46 |
| Warfarin | 251 | $4,489 | $18 |
| Digoxin | 55 | $2,305 | $42 |
| Isosorbide Mononitrate Er | 67 | $2,265 | $34 |
| Torsemide | 90 | $2,261 | $25 |
| Propranolol Hcl Er | 13 | $2,228 | $171 |
| Nitroglycerin Patch | 43 | $2,226 | $52 |
| Labetalol | 34 | $1,855 | $55 |
| Lisinopril | 295 | $1,788 | $6 |
| Amlodipine Besylate | 257 | $1,627 | $6 |
| Losartan | 149 | $1,509 | $10 |
| Furosemide | 268 | $1,321 | $5 |
| Nitroglycerin | 35 | $1,145 | $33 |
| Spironolactone | 87 | $1,092 | $13 |
| Sotalol | 41 | $1,090 | $27 |
| Pravastatin | 59 | $1,078 | $18 |
| Doxazosin Mesylate | 34 | $1,014 | $30 |
| Cartia Xt | 25 | $1,010 | $40 |
| Verapamil Er | 17 | $967 | $57 |
| Atenolol | 72 | $943 | $13 |
| Tiazac | 11 | $937 | $85 |
| Toprol Xl | 17 | $933 | $55 |
| Digox | 19 | $919 | $48 |
| Clopidogrel | 106 | $915 | $9 |
| Potassium Chloride | 25 | $889 | $36 |
| Amiodarone | 53 | $808 | $15 |
| Diltiazem 24hr Er | 18 | $794 | $44 |
| Hydrochlorothiazide | 94 | $534 | $6 |
| Simvastatin | 84 | $512 | $6 |
| Carvedilol | 73 | $479 | $7 |
| Dilt-Xr | 11 | $466 | $42 |
| Cilostazol | 18 | $463 | $26 |
| Metoprolol | 66 | $377 | $6 |
| Valsartan | 12 | $324 | $27 |
| Hydralazine | 18 | $318 | $18 |
| Pantoprazole | 18 | $203 | $11 |
| Omeprazole | 18 | $194 | $11 |
| Jantoven | 14 | $151 | $11 |
| Lisinopril-Hydrochlorothiazide | 24 | $149 | $6 |
| Triamterene-Hydrochlorothiazid | 14 | $138 | $10 |
| Amlodipine Besylate-Benazepril | 11 | $79 | $7 |
2017: 46 drugs
| Eliquis | 141 | $77,380 | $549 |
| Metoprolol | 674 | $20,318 | $30 |
| Xarelto | 23 | $16,490 | $717 |
| Ranexa | 20 | $6,635 | $332 |
| Rosuvastatin | 75 | $5,601 | $75 |
| Atorvastatin | 305 | $4,712 | $15 |
| Digoxin | 101 | $4,668 | $46 |
| Warfarin | 222 | $4,244 | $19 |
| Diltiazem 24hr Er | 104 | $3,586 | $34 |
| Colestipol | 12 | $2,949 | $246 |
| Lisinopril | 279 | $1,621 | $6 |
| Isosorbide Mononitrate Er | 59 | $1,598 | $27 |
| Labetalol | 29 | $1,483 | $51 |
| Nitroglycerin | 24 | $1,444 | $60 |
| Nitroglycerin Patch | 34 | $1,378 | $41 |
| Furosemide | 249 | $1,144 | $5 |
| Pravastatin | 38 | $1,039 | $27 |
| Amlodipine Besylate | 190 | $1,033 | $5 |
| Losartan | 137 | $929 | $7 |
| Toprol Xl | 12 | $873 | $73 |
| Torsemide | 28 | $750 | $27 |
| Spironolactone | 70 | $725 | $10 |
| Flecainide Acetate | 16 | $687 | $43 |
| Atenolol | 92 | $668 | $7 |
| Cartia Xt | 26 | $622 | $24 |
| Simvastatin | 99 | $584 | $6 |
| Potassium Chloride | 20 | $580 | $29 |
| Verapamil Er | 18 | $519 | $29 |
| Amiodarone | 27 | $499 | $18 |
| Clopidogrel | 65 | $475 | $7 |
| Sotalol | 26 | $455 | $18 |
| Cilostazol | 22 | $448 | $20 |
| Valsartan | 11 | $410 | $37 |
| Fenofibrate | 12 | $368 | $31 |
| Carvedilol | 64 | $364 | $6 |
| Metoprolol | 46 | $352 | $8 |
| Hydrochlorothiazide | 72 | $278 | $4 |
| Doxazosin Mesylate | 11 | $255 | $23 |
| Losartan-Hydrochlorothiazide | 11 | $237 | $22 |
| Pantoprazole | 21 | $200 | $10 |
| Omeprazole | 26 | $196 | $8 |
| Triamterene-Hydrochlorothiazid | 16 | $152 | $10 |
| Jantoven | 12 | $124 | $10 |
| Lisinopril-Hydrochlorothiazide | 24 | $118 | $5 |
| Gemfibrozil | 13 | $107 | $8 |
| Allopurinol | 11 | $20 | $2 |
2016: 18 drugs
| Eliquis | 13 | $8,016 | $617 |
| Metoprolol | 103 | $2,080 | $20 |
| Atorvastatin | 55 | $882 | $16 |
| Digoxin | 11 | $751 | $68 |
| Amiodarone | 12 | $695 | $58 |
| Diltiazem 24hr Er | 11 | $592 | $54 |
| Warfarin | 32 | $592 | $18 |
| Amlodipine Besylate | 31 | $294 | $9 |
| Furosemide | 58 | $280 | $5 |
| Isosorbide Mononitrate Er | 11 | $250 | $23 |
| Losartan | 16 | $213 | $13 |
| Torsemide | 14 | $192 | $14 |
| Lisinopril | 36 | $174 | $5 |
| Atenolol | 27 | $140 | $5 |
| Metoprolol | 13 | $127 | $10 |
| Carvedilol | 14 | $116 | $8 |
| Simvastatin | 14 | $90 | $6 |
| Hydrochlorothiazide | 11 | $33 | $3 |
2015: 2 drugs
| Atorvastatin | 12 | $240 | $20 |
| Amlodipine Besylate | 15 | $101 | $7 |
2014: 3 drugs
| Atorvastatin | 31 | $1,076 | $35 |
| Metoprolol | 19 | $968 | $51 |
| Amiodarone | 11 | $605 | $55 |
Money from drug and device companies
$1,858 in 2025
| 2025 | 16 | 55 | None | $1,858 |
| 2024 | 11 | 24 | None | $582 |
| 2023 | 10 | 31 | None | $845 |
| 2022 | 12 | 27 | None | $691 |
| 2021 | 9 | 23 | None | $528 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Cardiomems | $451 | 9 payments
|
| Medtronic | Aurora Ev-Icd Mri Surescan | $351 | 7 payments
|
| Novartis Pharmaceuticals | Leqvio | $189 | 7 payments
|
| Biosense Webster | Carto 3 | $147 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $145 | 6 payments
|
| Amgen | Repatha | $95 | 4 payments
|
See all 54 published payments
| Abbott Laboratories | Meals · 2025-12-31 | Cardiomems | $158 |
| Amgen | Meals · 2025-12-17 | Repatha | $15 |
| Biosense Webster | Meals · 2025-12-12 | Carto 3 | $147 |
| Medtronic | Meals · 2025-12-12 | Aurora Ev-Icd Mri Surescan | $113 |
| Boston Scientific | Meals · 2025-12-09 | Watchman Flx | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-08 | Eliquis | $15 |
| Esperion Therapeutics | Meals · 2025-12-04 | Nexletol | $23 |
| Amgen | Meals · 2025-11-14 | Repatha | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-13 | Jardiance | $28 |
| Novo Nordisk | Meals · 2025-11-12 | Wegovy | $33 |
| Abbott Laboratories | Meals · 2025-11-11 | Amplatzer Amulet | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-05 | Eliquis | $25 |
| Novartis Pharmaceuticals | Meals · 2025-11-04 | Leqvio | $30 |
| Cleerly | Meals · 2025-10-21 | Cleerly Ischemia | $16 |
| Medtronic | Meals · 2025-10-14 | Aurora Ev-Icd Mri Surescan | $58 |
| Amgen | Meals · 2025-10-07 | Repatha | $31 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-10-06 | Lifevest | $17 |
| Medtronic | Meals · 2025-10-02 | Aurora Ev-Icd Mri Surescan | $9 |
| Medtronic | Meals · 2025-10-01 | Omniasecure Mri Surescan | $82 |
| Pfizer | Meals · 2025-09-30 | Eliquis | $28 |
| Amgen | Meals · 2025-09-29 | Repatha | $31 |
| Novartis Pharmaceuticals | Meals · 2025-09-25 | Leqvio | $35 |
| Medtronic | Meals · 2025-09-24 | Mycarelink | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-23 | Jardiance | $17 |
| Novo Nordisk | Meals · 2025-09-22 | Wegovy | $33 |
| Novo Nordisk | Meals · 2025-09-16 | Wegovy | $26 |
| Novartis Pharmaceuticals | Meals · 2025-09-15 | Leqvio | $4 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-19 | Jardiance | $26 |
| Abbott Laboratories | Meals · 2025-08-07 | Cardiomems | $33 |
| Heartflow | Meals · 2025-08-05 | Ffrct | $40 |
| Novartis Pharmaceuticals | Meals · 2025-07-29 | Leqvio | $30 |
| Medtronic | Meals · 2025-07-22 | Mycarelink | $42 |
| Abbott Laboratories | Meals · 2025-07-15 | Cardiomems | $31 |
| Boston Scientific | Meals · 2025-07-10 | Watchman Flx | $23 |
| Abbott Laboratories | Meals · 2025-07-09 | Cardiomems | $124 |
| Edwards Lifesciences | Meals · 2025-06-27 | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $22 |
| Novartis Pharmaceuticals | Meals · 2025-06-26 | Leqvio | $23 |
| Abbott Laboratories | Meals · 2025-06-09 | Cardiomems | $34 |
| Baxter Healthcare | Meals · 2025-06-06 | Hillrom - Carnation Ambulatory Monitor | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-29 | Jardiance | $31 |
| Novartis Pharmaceuticals | Meals · 2025-05-20 | Leqvio | $35 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-19 | Eliquis | $24 |
| Boston Scientific | Meals · 2025-04-26 | Watchman Flx | $20 |
| Medtronic | Meals · 2025-04-22 | Symplicity G3 | $23 |
| Pfizer | Meals · 2025-04-15 | Eliquis | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-14 | Jardiance | $24 |
| Abbott Laboratories | Meals · 2025-03-27 | Cardiomems | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-25 | Eliquis | $22 |
| Abbott Laboratories | Meals · 2025-03-05 | Cardiomems | $20 |
| Abbott Laboratories | Meals · 2025-03-05 | Cardiomems | $4 |
| Novartis Pharmaceuticals | Meals · 2025-01-21 | Leqvio | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-14 | Jardiance | $19 |
| Boston Scientific | Meals · 2025-01-07 | Watchman Flx | $13 |
| Pfizer | Meals · 2025-01-06 | Eliquis | $27 |
See earlier years (2024, 2023, 2022, 2021)
2024: $582
| Novartis Pharmaceuticals | Leqvio | $166 | 7 payments
|
| Abbott Laboratories | Cardiomems | $111 | 3 payments
|
| Boston Scientific | Watchman Flx | $76 | 4 payments
|
| Esperion Therapeutics | Nexletol | $42 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $39 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $31 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $30 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $27 | 1 payment
|
| Pfizer | Eliquis | $23 | 1 payment
|
| Amgen | Repatha | $19 | 1 payment
|
| Heartflow | Ffrct | $17 | 1 payment
|
2023: $845
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $177 | 4 payments
|
| Esperion Therapeutics | Nexletol | $123 | 6 payments
|
| Novo Nordisk | None | $122 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $115 | 5 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $93 | 6 payments
|
| Abbott Laboratories | Cardiomems | $85 | 3 payments
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $73 | 3 payments
|
| Amgen | Repatha | $23 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $17 | 1 payment
|
| Boston Scientific | Watchman Flx | $15 | 1 payment
|
2022: $691
| AstraZeneca Pharmaceuticals LP | Farxiga | $140 | 2 payments
|
| Alnylam Pharmaceuticals | Onpattro | $106 | 4 payments
|
| Esperion Therapeutics | Nexletol | $101 | 5 payments
|
| Abbott Laboratories | Gallant | $86 | 3 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $83 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $58 | 3 payments
|
| iRhythm Technologies | Zio Xt Patch | $22 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $22 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $20 | 1 payment
|
| Amgen | Repatha | $18 | 1 payment
|
| Novo Nordisk | Ozempic | $16 | 1 payment
|
2021: $528
| Novo Nordisk | Ozempic | $131 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $115 | 7 payments
|
| Novartis Pharmaceuticals | Entresto | $79 | 4 payments
|
| Esperion Therapeutics | Nexletol | $54 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $47 | 3 payments
|
| Amgen | Repatha | $37 | 2 payments
|
| Abbott Laboratories | Quadra Assura Crt Defibrillator | $25 | 1 payment
|
| Amarin Pharma | Vascepa | $20 | 1 payment
|
| Kiniksa Pharmaceuticals | None | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1942521497
- Licence
- MA 244522
- Trained
- Drexel University College of Medicine, 2010 · 16 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 2490 Hospital Dr Ste 311, Mountain View, CA, 94040
- NPI first listed
- 2010-06-18
- NPI last updated
- 2025-05-06
- NPI record certified
- 2025-05-06
This is when the NPI record was last certified, not a medical board exam.